Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis

The Lancet HIV

Volumn 3, Issue 11, 2016, Pages e510-e520

  Kanters, Steve ^a,b   Vitoria, Marco ^c   Doherty, Meg ^c   Socias, Maria Eugenia ^a   Ford, Nathan ^c   Forrest, Jamie I ^a,b   Popoff, Evan ^a   Bansback, Nick ^b   Nsanzimana, Sabin ^d   Thorlund, Kristian ^a   Mills, Edward J ^a,e  

^a Department of Health Analytics   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d RWANDA BIOMEDICAL CENTER   (Rwanda)

^e UNIVERSITY OF RWANDA   (Rwanda)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; COBICISTAT; DARUNAVIR; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; SAQUINAVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; BENZOXAZINE DERIVATIVE; FUSED HETEROCYCLIC RINGS; INTEGRASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BIBLIOGRAPHIC DATABASE; COUNTRY ECONOMIC STATUS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADOLESCENT; ADULT; BAYES THEOREM; CHILD; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DRUG EFFECTS; FEMALE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MIDDLE AGED; NETWORK META-ANALYSIS; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; BAYES THEOREM; BENZOXAZINES; CHILD; CLINICAL TRIALS AS TOPIC; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; NETWORK META-ANALYSIS; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD; YOUNG ADULT;

EID: 84994706913     PISSN: None     EISSN: 23523018     Source Type: Journal    
DOI: 10.1016/S2352-3018(16)30091-1     Document Type: Article

References (154)

1. 1 UNAIDS. Fact Sheet 2016. http://www.unaids.org/en/resources/fact-sheet (accessed June 16, 2016).
2. 2 Braitstein, P, Brinkhof, MW, Dabis, F, et al. the Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration, the ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367 (2006), 817–824.
3. 3 Cohen, MS, Chen, YQ, McCauley, M, et al., the HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365 (2011), 493–505.
4. 4 Tanser, F, Bärnighausen, T, Grapsa, E, Zaidi, J, Newell, ML, High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 339 (2013), 966–971.
5. 5 The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 373 (2015), 795–807.
6. 6 The TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 373 (2015), 808–822.
7. 7 WHO. Global update on HIV treatment 2013: results, impact and opportunities. http://www.who.int/hiv/pub/progressreports/update2013/en/, 2013 (accessed March 15, 2016).
8. 8 Günthard, HF, Aberg, JA, Eron, JJ, et al., the International Antiviral Society-USA Panel. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel. JAMA 312 (2014), 410–425.
9. 9 Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf (accessed March 15, 2016).
10. 10 Mills, EJ, Ioannidis, JP, Thorlund, K, Schünemann, HJ, Puhan, MA, Guyatt, GH, How to use an article reporting a multiple treatment comparison meta-analysis. JAMA 308 (2012), 1246–1253.
11. 11 Gray, A, Vitoria, M, Technical update on treatment optimisation: Pharmacological equivalence and clinical interchangeability of lamivudine and emtricitabine: a review of current literature, 2012, World Health Organization, France.
12. 12 DerSimonian, R, Laird, N, Meta-analysis in clinical trials. Control Clin Trials 7 (1986), 177–188.
13. 13 Higgins, JPT, Altman, DG, Gøtzsche, PC, et al. the Cochrane Bias Methods Group, the Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928.
14. 14 Salanti, G, Higgins, JPT, Ades, AE, Ioannidis, JPA, Evaluation of networks of randomized trials. Stat Methods Med Res 17 (2008), 279–301.
15. 15 Lu, G, Ades, AE, Assessing evidence inconsistency in mixed treatment comparisons. J Am Stat Assoc 101 (2006), 447–459.
16. 16 Dias, S, Welton, N, Sutton, A, Ades, A, Technical support document 2: a generalized linear modelling framework for pairwise and network meta-analysis of randomized controlled trials. http://www.nicedsu.org.uk/TSD2%20General%20meta%20analysis%20corrected%2015April2014.pdf, 2011 (accessed Feb 5, 2016).
17. 17 Dias, S, Welton, NJ, Sutton, AJ, Caldwell, DM, Lu, G, Ades, AE, Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making 33 (2013), 641–656.
18. 18 Guyatt, GH, Oxman, AD, Kunz, R, et al. GRADE guidelines 6. Rating the quality of evidence—imprecision. J Clin Epidemiol 64 (2011), 1283–1293.
19. 19 Puhan, MA, Schunemann, HJ, Murad, MH, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ, 349, 2014, g5630.
20. 20 Aberg, JA, Tebas, P, Overton, ET, et al. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks. AIDS Res Hum Retroviruses 28 (2012), 1184–1195.
21. 21 Albini, L, Cesana, BM, Motta, D, et al. A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz. J Acquir Immune Defic Syndr 59 (2012), 18–30.
22. 22 Puls, R, Amin, J, Losso, M, et al., the ENCORE1 Study Group. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet 383 (2014), 1474–1482.
23. 23 Carey, D, Puls, R, Amin, J, et al., for the ENCORE1 Study Group. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis 15 (2015), 793–802.
24. 24 Arathoon, E, Schneider, S, Baraldi, E, et al. Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS. Int J STD AIDS 24 (2013), 12–17.
25. 25 Arribas, JR, Pozniak, AL, Gallant, JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 47 (2008), 74–78.
26. 26 Berenguer, J, González, J, Ribera, E, et al., the GESIDA 3903 Team. Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903. Clin Infect Dis 47 (2008), 1083–1092.
27. 27 Bertz, RJ, Persson, A, Chung, E, et al. Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve. Pharmacotherapy 33 (2013), 284–294.
28. 28 Campbell, TB, Smeaton, LM, Kumarasamy, N, et al., the PEARLS study team of the ACTG. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med, 9, 2012, e1001290.
29. 29 Carr, A, Chuah, J, Hudson, J, et al. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study. AIDS 14 (2000), 1171–1180.
30. 30 Clotet, B, Feinberg, J, van Lunzen, J, et al., the ING114915 Study Team. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 383 (2014), 2222–2231.
31. 31 Cohan, D, Natureeba, P, Koss, CA, et al. Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women. AIDS 29 (2015), 183–191.
32. 32 Cohen, C, Elion, R, Ruane, P, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 25 (2011), F7–12.
33. 33 Cohen, C, Wohl, D, Arribas, J, et al. STAR Study: Single tablet regimen emtricitabine/rilpivirine/tenofovir DF is non-inferior to efavirenz/emtricitabine/tenofovir DF in ART-naive adults. J Int AIDS Soc, 15, 2012, 24.
34. 34 Cohen, C, Wohl, D, Arribas, JR, et al. Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. AIDS 28 (2014), 989–997.
35. 35 Cohen, CJ, Andrade-Villanueva, J, Clotet, B, et al., the THRIVE study group. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 378 (2011), 229–237.
36. 36 Yeni, P, Cooper, DA, Aboulker, JP, et al., the INITIO Trial International Coordinating Committee. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Lancet 368 (2006), 287–298.
37. 37 Curtis LD, Min S, Nichols G, et al, SPRING-2 and SINGLE teams. Once-daily dolutegravir (DTG; S/GSK1349572) has a renal safety profile comparable to raltegravir (RAL) and efavirenz in antiretroviral (ART)-naïve adults: 48 week results from SPRING-2 (ING113086) and SINGLE (ING114467). 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Kuala Lumpur, Malaysia; June 30–July 3, 2013. TUPE282.
38. 38 Daar, ES, Tierney, C, Fischl, MA, et al., the AIDS Clinical Trials Group Study A5202 Team. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 154 (2011), 445–456.
39. 39 Dart Trial Team. Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA). Trop Med Int Health 13 (2008), 6–16.
40. 40 DeJesus, E, Herrera, G, Teofilo, E, et al., the CNA30024 Study Team. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 39 (2004), 1038–1046.
41. 41 Dejesus, E, Mills, A, Bhatti, L, Conner, C, Storfer, S, A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients. Int J Clin Pract 65 (2011), 1240–1249.
42. 42 DeJesus, E, Rockstroh, JK, Henry, K, et al., the GS-236-0103 Study Team. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet 379 (2012), 2429–2438.
43. 43 DeJesus, E, Rockstroh, JK, Lennox, JL, et al., the STARTMRK Investigators. Efficacy of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients: week-192 overall and subgroup analyses from STARTMRK. HIV Clin Trials 13 (2012), 228–232.
44. 44 Echeverría, P, Negredo, E, Carosi, G, et al. Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study). Antiviral Res 85 (2010), 403–408.
45. 45 Eron, J Jr, Yeni, P, Gathe, J Jr, et al., the KLEAN study team. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 368 (2006), 476–482.
46. 46 Fatkenheuer, G, Kelly, M, Van Wijngaerden, E, et al. ARTEMIS 96-week comparison of liver tolerability of once-daily darunavir/ritonavir (DRV/r) versus lopinavir/ritonavir (LPV/r) in treatment-naive patients. HIV Med, 10, 2009, 100.
47. 47 Fisac, C, Virgili, N, Ferrer, E, et al. A comparison of the effects of nevirapine and nelfinavir on metabolism and body habitus in antiretroviral-naive human immunodeficiency virus-infected patients: a randomized controlled study. J Clin Endocrinol Metab 88 (2003), 5186–5192.
48. 48 French, M, Amin, J, Roth, N, et al., the OzCombo 2 investigators. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study. HIV Clin Trials 3 (2002), 177–185.
49. 49 Gallant, JE, DeJesus, E, Arribas, JR, et al., the Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 354 (2006), 251–260.
50. 50 Gallant, JE, Staszewski, S, Pozniak, AL, et al., the 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 292 (2004), 191–201.
51. 51 Gathe, JC Jr, Ive, P, Wood, R, et al. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients. AIDS 18 (2004), 1529–1537.
52. 52 Gotti, D, Cesana, BM, Albini, L, et al. Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavir. HIV Clin Trials 13 (2012), 245–255.
53. 53 Gotuzzo, E, Markowitz, M, Ratanasuwan, W, et al., the Protocol 004 Study Team. Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized, controlled, phase II study (Protocol 004). J Acquir Immune Defic Syndr 61 (2012), 73–77.
54. 54 Grinsztejn, B, De Castro, N, Arnold, V, et al., the ANRS 12 180 Reflate TB study group. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. Lancet Infect Dis 14 (2014), 459–467.
55. 55 Gulick, RM, Ribaudo, HJ, Shikuma, CM, et al., the AIDS Clinical Trials Group (ACTG) A5095 Study Team. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 296 (2006), 769–781.
56. 56 Gulick, RM, Ribaudo, HJ, Shikuma, CM, et al., the AIDS Clinical Trials Group Study A5095 Team. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 350 (2004), 1850–1861.
57. 57 Harris, M, Côté, H, Ochoa, C, et al., the CTN 177 Study Team. A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients. J Acquir Immune Defic Syndr 50 (2009), 335–337.
58. 58 Harris MCO, Allavena C, Negredo E, et al, the CTN 177 study team. NRTI sparing trial (CTN 177): antiviral and metabolic effects of nevirapine (NVP) + lopinavir/ritonavir (LPV/r) vs. zidovudine/lamivudine (AZT/3TC) + NVP vs. AZT/3TC + LPV/r. International AIDS Conference; Melbourne, Australia; 2014.
59. 59 Haubrich, RH, Riddler, SA, DiRienzo, AG, et al., the AIDS Clinical Trials Group (ACTG) A5142 Study Team. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 23 (2009), 1109–1118.
60. 60 Honda, M, Ishisaka, M, Ishizuka, N, Kimura, S, Oka, S, the Japanese Anti-HIV-1 QD Therapy Study Group. Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine. Intern Med 50 (2011), 699–705.
61. 61 Izzedine, H, Hulot, JS, Vittecoq, D, et al., the Study 903 Team. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 20 (2005), 743–746.
62. 62 Jemsek, JG, Arathoon, E, Arlotti, M, et al. Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis 42 (2006), 273–280.
63. 63 Johnson, M, Moyle, G, CASTLE study: 96-week efficacy & safety of ATV/r versus LPV/r in antiretroviral-naive HIV-1-infected patients. HIV Med, 10, 2009, 17.
64. 64 Kappelhoff, BS, van Leth, F, Robinson, PA, et al., the 2NN Study Group. Are adverse events of nevirapine and efavirenz related to plasma concentrations?. Antivir Ther 10 (2005), 489–498.
65. 65 Kumar, P, DeJesus, E, Huhn, G, et al., the SUPPORT Study Team. Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results. BMC Infect Dis, 13, 2013, 269.
66. 66 Kumar, PN, Salvato, P, Lamarca, A, et al. A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study). AIDS Res Ther, 6, 2009, 3.
67. 67 Landman, R, Koulla-Shiro, S, Sow, PS, et al., the DAYANA Study Group. Evaluation of four tenofovir-containing regimens as first-line treatments in Cameroon and Senegal: the ANRS 12115 DAYANA Trial. Antivir Ther 19 (2014), 51–59.
68. 68 Lazzarin, A, Orkin, C, De Jesus, E, et al. Artemis: 192-Week efficacy and safety of once daily darunavir/ritonavir (DRV/r) versus lopinavir/R (LPV/r) in treatment-naive HIV-1-infected adults. Infection 39 (2011), S26–S27.
69. 69 Lennox, JL, Dejesus, E, Berger, DS, et al., the STARTMRK Investigators. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 55 (2010), 39–48.
70. 70 Lennox, JL, DeJesus, E, Lazzarin, A, et al., the STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 374 (2009), 796–806.
71. 71 Lennox, JL, Landovitz, RJ, Ribaudo, HJ, et al., the ACTG A5257 Team. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med 161 (2014), 461–471.
72. 72 Li, T, Dai, Y, Kuang, J, et al. Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort. PLoS One, 3, 2008, e3918.
73. 73 Maggiolo, F, Ripamonti, D, Gregis, G, et al. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Antivir Ther 8 (2003), 339–346.
74. 74 Malan, DR, Krantz, E, David, N, et al., the 089 Stuy Group. 96-week efficacy and safety of atazanavir, with and without ritonavir, in a HAART regimen in treatment-naive patients. J Int Assoc Physicians AIDS Care (Chic) 9 (2010), 34–42.
75. 75 Malan, DR, Krantz, E, David, N, Wirtz, V, Hammond, J, McGrath, D, the 089 Study Group. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr 47 (2008), 161–167.
76. 76 Malan, N, Su, J, Mancini, M, et al., the CASTLE Study Team. Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study. AIDS Care 22 (2010), 677–686.
77. 77 Mankhatitham, W, Lueangniyomkul, A, Manosuthi, W, Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen. Southeast Asian J Trop Med Public Health 42 (2011), 651–658.
78. 78 Manosuthi, W, Sungkanuparph, S, Tantanathip, P, et al., the N2R Study Team. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study. Clin Infect Dis 48 (2009), 1752–1759.
79. 79 Markowitz, M, Nguyen, BY, Gotuzzo, E, et al., the Protocol 004 Part II Study Team. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr 52 (2009), 350–356.
80. 80 Markowitz, M, Nguyen, BY, Gotuzzo, E, et al., the Protocol 004 Part II Study Team. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 46 (2007), 125–133.
81. 81 Martinez, E, Gonzalez-Cordon, A, Ferrer, E, et al., the ATADAR Study Group. Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir. HIV Med 15 (2014), 330–338.
82. 82 Martinez-Picado, J, Negredo, E, Ruiz, L, et al., the SWATCH Study Team. Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial. Ann Intern Med 139 (2003), 81–89.
83. 83 Matheron, S, Descamps, D, Boué, F, et al., the CNA3007 Study Group. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antivir Ther 8 (2003), 163–171.
84. 84 Matthews, GV, Manzini, P, Hu, Z, et al., the PHIDISA II study team. Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa. AIDS 25 (2011), 1727–1735.
85. 85 Mills, AM, Nelson, M, Jayaweera, D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 23 (2009), 1679–1688.
86. 86 Min S, Roberts J, Almond S, et al. Efficacy and safety of dolutegravir (DTG) in hepatitis (HBV or HCV) co-infected patients: results from the phase 3 program 20th International AIDS Conference; Melbourne, Australia; 2014.
87. 87 Molina, JM, Clotet, B, van Lunzen, J, et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV 2 (2015), e127–e136.
88. 88 Molina, JM, Andrade-Villanueva, J, Echevarria, J, et al., the CASTLE Study Team. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 372 (2008), 646–655.
89. 89 Molina, JM, Andrade-Villanueva, J, Echevarria, J, et al., the CASTLE Study Team. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defic Syndr 53 (2010), 323–332.
90. 90 Molina, JM, Cahn, P, Grinsztejn, B, et al., the ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 378 (2011), 238–246.
91. 91 Moyle, GJ, Stellbrink, HJ, Compston, J, et al., the ASSERT Team. 96-week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. Antivir Ther 18 (2013), 905–913.
92. 92 Munderi, P, Walker, AS, Kityo, C, et al., the DART/NORA trial teams. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts. HIV Med 11 (2010), 334–344.
93. 93 Murphy, RL, Sanne, I, Cahn, P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 17 (2003), 2603–2614.
94. 94 Murray, JM, Emery, S, Kelleher, AD, et al. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS 21 (2007), 2315–2321.
95. 95 Nathan, C, Jean-Michel, M, Keith, H, et al. Long-term efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir plus ritonavir plus emtricitabine/tenofovir. J Int AIDS Soc 17 (2014), 23–24.
96. 96 Natureeba, P, Ades, V, Luwedde, F, et al. Lopinavir/ritonavir-based antiretroviral treatment (ART) versus efavirenz-based ART for the prevention of malaria among HIV-infected pregnant women. J Infect Dis 210 (2014), 1938–1945.
97. 97 Ndembi, N, Goodall, RL, Dunn, DT, et al., the Development of Antiretroviral Treatment in Africa Virology Group and Trial Team. Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir. J Infect Dis 201 (2010), 106–113.
98. 98 Negredo, E, Paredes, R, Peraire, J, et al., the Swatch Study Team. Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study. Antivir Ther 9 (2004), 889–893.
99. 99 Nishijima, T, Komatsu, H, Teruya, K, et al. Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml. AIDS 27 (2013), 839–842.
100. 100 Nishijima, T, Takano, M, Ishisaka, M, et al., the Epzicom-Truvada study team. Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial. Intern Med 52 (2013), 735–744.
101. 101 Núñez, M, Soriano, V, Martín-Carbonero, L, et al. SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals. HIV Clin Trials 3 (2002), 186–194.
102. 102 Orkin, C, Clumeck, N, Girard, PM, et al. Week 144 efficacy and safety data: elvitegravir/cobicistat/emtricitabine/tenofovir DF (stribild) demonstrates durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF at week 144 in treatment-naive HIV-1-infected patients. HIV Med, 15, 2014, 114.
103. 103 Orkin, C, DeJesus, E, Khanlou, H, et al. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial. HIV Med 14 (2013), 49–59.
104. 104 Orkin, C, Rockstroh, J, DeJesus, E, et al. Week 96 efficacy and safety data: Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF in treatment-naive HIV-1-infected patients. HIV Med, 14, 2013, 56.
105. 105 Orkin, C, Stebbing, J, Nelson, M, et al. A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study). J Antimicrob Chemother 55 (2005), 246–251.
106. 106 Ortiz, R, Dejesus, E, Khanlou, H, et al. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS 22 (2008), 1389–1397.
107. 107 Phanuphak, N, Ananworanich, J, Teeratakulpisarn, N, et al., the SEARCH 003 Study Group. A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine. Antivir Ther 17 (2012), 1521–1531.
108. 108 Podzamczer, D, Andrade-Villanueva, J, Clotet, B, et al. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). HIV Med 12 (2011), 374–382.
109. 109 Podzamczer, D, Ferrer, E, Consiglio, E, et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antivir Ther 7 (2002), 81–90.
110. 110 Podzamczer, D, Soriano, V, Andrade-Villanueva, J, et al. Comparison of lipid profile with nevirapine versus atazanavir/ritonavir, both combined with tenofovir DF and emtricitabine (TDF/FTC), in treatment-naive HIV-1-infected patients: ARTEN study week-48 results. HIV Med, 10, 2009, 26.
111. 111 Post, FA, Moyle, GJ, Stellbrink, HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 55 (2010), 49–57.
112. 112 Pozniak, AL, Gallant, JE, DeJesus, E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes–a 96-week analysis. J Acquir Immune Defic Syndr 43 (2006), 535–540.
113. 113 Pozniak, AL, Morales-Ramirez, J, Katabira, E, et al., the TMC278-C204 Study Group. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS 24 (2010), 55–65.
114. 114 Puls, RL, Srasuebkul, P, Petoumenos, K, et al., the Altair Study Group. Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study. Clin Infect Dis 51 (2010), 855–864.
115. 115 Raffi, F, Jaeger, H, Quiros-Roldan, E, et al., the extended SPRING-2 Study Group. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 13 (2013), 927–935.
116. 116 Raffi, F, Rachlis, A, Stellbrink, HJ, et al., the SPRING-2 Study Group. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 381 (2013), 735–743.
117. 117 Ratsela, A, Polis, M, Dhlomo, S, et al., the Phidisa II Writing Team for Project Phidisa. A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa. J Infect Dis 202 (2010), 1529–1537.
118. 118 Rey, D, Hoen, B, Chavanet, P, et al. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. J Antimicrob Chemother 63 (2009), 380–388.
119. 119 Ribaudo, HJ, Kuritzkes, DR, Lalama, CM, et al. Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts. J Infect Dis 197 (2008), 1006–1010.
120. 120 Riddler, SA, Haubrich, R, DiRienzo, AG, et al., the AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 358 (2008), 2095–2106.
121. 121 Rockstroh, J, DeJesus, E, Henry, K, et al. Elvitegravir/cobicistat/emtricitabine/tenofovir DF (QUAD) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF at week 96 in treatment-naive HIV-1-infected patients. J Int AIDS Soc, 15, 2012, 23.
122. 122 Rockstroh J, Sklar P, Wan H, et al. Safety and efficacy of raltegravir in patients co-infected with HIV and hepatitis B and/or C virus: complete data from phase III double-blind studies. Eleventh International Congress on Drug Therapy in HIV Infection; Glasgow, Scotland; 2012.
123. 123 Rockstroh, JK, DeJesus, E, Henry, K, et al., the GS-236-0103 Study Team. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 62 (2013), 483–486.
124. 124 Rockstroh, JK, DeJesus, E, Lennox, JL, et al., the STARTMRK Investigators. Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. J Acquir Immune Defic Syndr 63 (2013), 77–85.
125. 125 Rockstroh, JK, Lennox, JL, Dejesus, E, et al., the STARTMRK Investigators. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 53 (2011), 807–816.
126. 126 Sax, PE, DeJesus, E, Mills, A, et al., the GS-US-236-0102 study team. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 379 (2012), 2439–2448.
127. 127 Sax, PE, Tierney, C, Collier, AC, et al., the AIDS Clinical Trials Group Study A5202 Team. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 204 (2011), 1191–1201.
128. 128 Sierra-Madero, J, Villasis-Keever, A, Méndez, P, et al. Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico. J Acquir Immune Defic Syndr 53 (2010), 582–588.
129. 129 Sinha, S, Raghunandan, P, Chandrashekhar, R, et al. Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study. BMC Infect Dis, 13, 2013, 482.
130. 130 Smith, KY, Patel, P, Fine, D, et al., the HEAT Study Team. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 23 (2009), 1547–1556.
131. 131 Smith, KY, Weinberg, WG, Dejesus, E, et al., the ALERT (COL103952) Study Team. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther, 5, 2008, 5.
132. 132 Soriano, V, Arastéh, K, Migrone, H, et al., the ARTEN investigators. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther 16 (2011), 339–348.
133. 133 Squires, K, Lazzarin, A, Gatell, JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 36 (2004), 1011–1019.
134. 134 Squires, KE, Gulick, R, Tebas, P, et al. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I). AIDS 14 (2000), 1591–1600.
135. 135 Staszewski, S, Keiser, P, Montaner, J, et al., the CNAAB3005 International Study Team. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA 285 (2001), 1155–1163.
136. 136 Stellbrink, HJ, Orkin, C, Arribas, JR, et al., the ASSERT Study Group. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 51 (2010), 963–972.
137. 137 Stellbrink, HJ, Reynes, J, Lazzarin, A, et al., the SPRING-1 Team. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study. AIDS 27 (2013), 1771–1778.
138. 138 Torti, C, Quiros-Roldan, E, Regazzi, M, et al., the KARINA-SISTHER Collaboration Group of the MASTER Cohort. Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy. Antivir Ther 10 (2005), 505–513.
139. 139 van Leeuwen, R, Katlama, C, Murphy, RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 17 (2003), 987–999.
140. 140 van Leth, F, Phanuphak, P, Ruxrungtham, K, et al., the 2NN Study team. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 363 (2004), 1253–1263.
141. 141 van Leth, F, Phanuphak, P, Stroes, E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med, 1, 2004, e19.
142. 142 van Lunzen, J, Maggiolo, F, Arribas, JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 12 (2012), 111–118.
143. 143 Vibhagool, A, Cahn, P, Schechter, M, et al. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014). Curr Med Res Opin 20 (2004), 1103–1114.
144. 144 Vrouenraets, SM, Wit, FW, Fernandez Garcia, E, et al., the BASIC Study Group. Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients. HIV Med 12 (2011), 620–631.
145. 145 Walmsley, S, Avihingsanon, A, Slim, J, et al. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr 50 (2009), 367–374.
146. 146 Walmsley S, Berenguer J, Khuong-Josses MA, et al. Dolutegravir regimen statistically superior to tenofovir/emtricitabine/efavirenz: 96-wk data. Topics in Antiviral Medicine Conference: 21st Conference on Retroviruses and Opportunistic Infections; Boston, MA; March 3–6, 2014. 261–62.
147. 147 Walmsley, S, Bernstein, B, King, M, et al., the M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 346 (2002), 2039–2046.
148. 148 Walmsley, SL, Antela, A, Clumeck, N, et al., the SINGLE Investigators. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 369 (2013), 1807–1818.
149. 149 Wester, CW, Thomas, AM, Bussmann, H, et al. Non-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana. AIDS 24:suppl 1 (2010), S27–S36.
150. 150 Wilkin, A, Pozniak, AL, Morales-Ramirez, J, et al., the TMC278-C204 Study Group. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. AIDS Res Hum Retroviruses 28 (2012), 437–446.
151. 151 Wohl, DA, Cohen, C, Gallant, JE, et al., the GS-US-236-0102 Study Team. A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF versus single-tablet regimen efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. J Acquir Immune Defic Syndr 65 (2014), e118–e120.
152. 152 Zolopa, A, Sax, PE, DeJesus, E, et al. A randomized, double-blind comparison of co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 63 (2013), 96–100.
153. 153 Nolan, D, HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects. Crit Rev Clin Lab Sci 46 (2009), 153–165.
154. 154 WHO. Disease and injury regional mortality estimates, 2000–2011, 2012, World Health Organization, Geneva, Switzerland.